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Abstract 
[18F]Fluorodeoxyglucose ([18F]FDG) is a positron emission radiotracer whose biodistribution is similar to glucose. The similar 
biodistribution of [18F]FDG and glucose in the human body requires a fasting condition for at least six hours prior to performing a 
[18F]FDG positron emission tomography ([18F]FDG PET) study.
In human studies, FDG PET images, in either the fasting state or the glucose-loaded state, have demonstrated that [18F]FDG uptake is 
decreased in the tumour, and thus the PET image quality is impaired, when plasma glucose levels are increased. All these results 
suggest that patients should fast before FDG PET studies, and their plasma glucose concentration needs to be considered when 
assessing tumour glucose metabolism. However, for lymphomatous disease, the data are contradictory and there are reports that insulin 
does not induce major changes in glucose uptake of lymphomatous tissue. 
Here, we report two cases of lymphoma in which [18F]FDG PET/computed tomography ([18F]FDG PET/CT) was used for chemotherapy 
response evaluation. In both cases, initial [18F]FDG PET/CT scans were negative for neoplastic lesions but showed increased and 
diffuse FDG uptake in muscles. This led us to investigate better the importance of a fasting condition. A second [18F]FDG PET/CT 
performed 3–4 days later revealed pathological uptake in the lymphomatous lesions in both cases. 
We demonstrate the importance of a euglycemic state before [18F]FDG administration, and that a fasting period of at least six hours is 
required prior to administration. 
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Malignant cancer cells are characterized by increased glucose 
metabolism [1] as documented in fast-growing, poorly 
differentiated tumours [2]. Hyper-metabolism of glucose 
depends on an increased rate of glucose transport through the 
cell membrane, decreased rate of dephosphorylation and 
enhanced activity of key glycolytic enzymes (e.g. hexokinase) 
[3]. 
Fluorodeoxyglucose is a positron emission radiotracer whose 
biodistribution is similar to glucose, and for this reason, it is 
currently considered the radiotracer of choice to detect 
malignant cancer cells. The similar biodistribution of FDG and 
glucose in the human body justify the requirement for a fasting 
condition prior to the performance of FDG PET studies. 
From the literature, we know that in the presence of high-
plasma glucose levels FDG uptake is enhanced in cardiac and 
skeletal muscles [4] and in vitro studies indicate that FDG 
accumulation in cancer cells will decline with increasing glucose 
levels [5] and, similarly, in tumours of rodents, a decrease of the 
mean FDG uptake has been observed at very high blood 
glucose and insulin levels [6]. 
Also, in vivo studies indicate that FDG uptake is markedly 
diminished by acute hyperglycaemia because of direct 
competition between FDG and D-glucose for tumour uptake 
[5,7]. In human studies, FDG PET images obtained in either the 
fasting state or the glucose-loaded state have demonstrated 
that tumour FDG uptake is decreased, and thus the PET image 
quality is impaired, when plasma glucose levels are increased 
[8,9]. All these results suggest that patients should fast before 
FDG PET studies, and their plasma glucose concentration 
needs to be considered when assessing tumour glucose 
metabolism [10]. 
On the contrary, Minn [11] reported contrasting data regarding 
FDG uptake in lymphomatous tissue in euglycaemic 
hyperinsulinaemic clamp and in the euglycaemic state under 
fasting conditions. He found that insulin does not induce major 
changes in glucose uptake of lymphomatous tissue. Although 
the insulin sensitivity of skeletal muscle was also reduced in 
patients with lymphoma, the net insulin effect may counteract 
imbalance between glucose uptake of tumour and muscle, 
offering a potential means to circumvent at least some 
metabolic abnormalities found in cancer. The adequate 
knowledge of the influence of hyperinsulinaemia on FDG 
uptake in human tumours needs to be better understood. 
Here, we report two cases of lymphoma in which repeat FDG 
PET/CT scans were carried out at an interval of four days. 
The first case is a 24-year-old woman with a diffuse large B cell 
non-Hodgkin lymphoma (DLBC). PET evaluation was required 
for early therapy response evaluation after three cycles of 
chemotherapy (regimen R-ACOD). 
The first FDG PET/CT revealed a diffuse and intense FDG 
uptake in skeletal muscle without evidence of increased uptake 
in the area known to be the site of a previous lymphoma (Figure 
1a). This scan was further investigated by the medical 
physician, who after speaking with the patient, realized that she 
had eaten breakfast three hours before so presumably she was 
in a hyperinsulinaemic euglycaemic state. Three days later, 
under a ‘strictly’ fasting condition, a second FDG PET/CT scan 
was performed revealing a focal FDG uptake in a lung nodule in 
the upper left lobe, as residual disease. Maximal standardized 
uptake volume was 6.6 (Figure 1b). 
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Figure 1: FDG PET/CT of a 24-year-old woman with non-Hodgkin's lymphoma. 
 
 
Figure 2: FDG PET/CT of a 38-year-old man with Hodgkin's disease.
The second case is a 38-year-old man with Hodgkin's disease 
(nodular sclerosis) that required PET evaluation as follow-up. 
The first FDG PET/CT revealed, as in the first case, a diffuse 
and intense FDG uptake in skeletal muscle with two low-uptake 
areas in the mediastinum (Figure 2a). The medical physician 
speaking with the patient knew that the patient ate a candy one 
hour before the FDG injection. Four days later a second FDG 
PET/CT scan was performed, revealing two areas of intense, 
focal FDG uptake (Figure 2b). Maximal standardized uptake 
volume was 8.03 (in non-fasting condition 2.65) and 4.65 (in 
non-fasting condition 2.23). 
We conclude that the fasting condition is an essential 
requirement when performing FDG PET and the timing of 
fasting is also essential. In conditions where the 4–6 hours of 
fasting has not been achieved, it is advised to wait, even in 
presence of a euglycaemic state. 
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